Metastatic Colorectal Cancer - Pipeline Review, H1 2014


#195041

389pages

Global Markets Direct

$ 2000

In Stock

Metastatic Colorectal Cancer - Pipeline Review, H1 2014

Summary

Global Markets Directs, Metastatic Colorectal Cancer - Pipeline Review, H1 2014, provides an overview of the Metastatic Colorectal Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Colorectal Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Colorectal Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Metastatic Colorectal Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Metastatic Colorectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Colorectal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Colorectal Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Colorectal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Metastatic Colorectal Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Metastatic Colorectal Cancer - Overview 11
Pipeline Products for Metastatic Colorectal Cancer - Comparative Analysis 12
Metastatic Colorectal Cancer - Therapeutics under Development by Companies 13
Metastatic Colorectal Cancer - Therapeutics under Investigation by Universities/Institutes 18
Metastatic Colorectal Cancer - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Unknown Stage Products 22
Metastatic Colorectal Cancer - Products under Development by Companies 23
Metastatic Colorectal Cancer - Products under Investigation by Universities/Institutes 28
Metastatic Colorectal Cancer - Companies Involved in Therapeutics Development 29
Bristol-Myers Squibb Company 29
Boehringer Ingelheim GmbH 30
F. Hoffmann-La Roche Ltd. 31
Amgen Inc. 32
AstraZeneca PLC 33
Eli Lilly and Company 34
Genentech, Inc. 35
Nektar Therapeutics 36
Bavarian Nordic A/S 37
Merck & Co., Inc. 38
Light Sciences Oncology, Inc. 39
Celltrion, Inc. 40
Millennium Pharmaceuticals, Inc. 41
Novartis AG 42
Biocon Limited 43
Nippon Kayaku Co., Ltd. 44
Pfizer Inc. 45
Taiho Pharmaceutical Co., Ltd. 46
Exelixis, Inc. 47
Bayer AG 48
Merck KGaA 49
Alchemia Limited 50
Immunomedics, Inc. 51
Oncolytics Biotech Inc. 52
Oncothyreon Inc. 53
Regeneron Pharmaceuticals, Inc. 54
Synta Pharmaceuticals Corp. 55
Panacea Biotec Limited 56
Morphotek, Inc. 57
Glycotope GmbH 58
Hutchison MediPharma Limited 59
TetraLogic Pharmaceuticals 60
Merrimack Pharmaceuticals, Inc. 61
Jennerex Biotherapeutics, Inc. 62
Syndax Pharmaceuticals, Inc. 63
Globeimmune, Inc. 64
AB Science 65
CureTech Ltd. 66
Biothera, Inc. 67
Medical Enzymes AG 68
Oncozyme Pharma Inc. 69
Karyopharm Therapeutics, Inc. 70
Immodulon Therapeutics Ltd. 71
Inbiopro Solutions Pvt. Ltd. 72
PsiOxus Therapeutics, Ltd. 73
AlphaMab Co., Ltd 74
Metastatic Colorectal Cancer - Therapeutics Assessment 75
Assessment by Monotherapy Products 75
Assessment by Combination Products 76
Assessment by Target 77
Assessment by Mechanism of Action 82
Assessment by Route of Administration 87
Assessment by Molecule Type 90
Drug Profiles 93
(tipiracil hydrochloride + trifluridine) - Drug Profile 93
regorafenib - Drug Profile 95
irinotecan hydrochloride - Drug Profile 97
ramucirumab - Drug Profile 99
(tipiracil hydrochloride + trifluridine) - Drug Profile 103
talaporfin sodium - Drug Profile 105
masitinib - Drug Profile 107
PGG beta-glucan - Drug Profile 109
etirinotecan pegol - Drug Profile 113
dalotuzumab - Drug Profile 116
PGG beta-glucan - Drug Profile 119
Recombinant Anti-Tumor And Anti-Viral Protein - Drug Profile 123
trebananib - Drug Profile 125
entinostat - Drug Profile 128
icrucumab - Drug Profile 132
DI-17-E-6 - Drug Profile 133
MK-2206 - Drug Profile 135
sorafenib tosylate - Drug Profile 138
axitinib - Drug Profile 142
gedatolisib - Drug Profile 146
onartuzumab - Drug Profile 148
selumetinib sulfate - Drug Profile 151
irinotecan hydrochloride - Drug Profile 154
pegdinetanib - Drug Profile 156
futuximab - Drug Profile 158
ganitumab - Drug Profile 160
pimasertib - Drug Profile 163
ganetespib - Drug Profile 165
MEK-162 - Drug Profile 169
pelareorep - Drug Profile 172
PX-866 - Drug Profile 176
ontuxizumab - Drug Profile 179
nintedanib - Drug Profile 181
GlutaDON - Drug Profile 183
pentamidine isethionate - Drug Profile 185
pidilizumab - Drug Profile 187
GI-4000 - Drug Profile 189
NK-012 - Drug Profile 191
afatinib - Drug Profile 193
imgatuzumab - Drug Profile 196
RG-7597 - Drug Profile 198
birinapant - Drug Profile 200
IMMU-130 - Drug Profile 202
(tegafur + gimeracil + oteracil potassium) - Drug Profile 203
IMM-101 - Drug Profile 206
Dendritic Cell Vaccine - Drug Profile 207
CV-301 - Drug Profile 208
celecoxib + [capecitabine] - Drug Profile 209
rilotumumab - Drug Profile 210
sapitinib - Drug Profile 212
cetuximab biobetter - Drug Profile 214
pexastimogene devacirepvec - Drug Profile 215
BYL-719 - Drug Profile 217
PGG beta-glucan - Drug Profile 219
ColoAd-1 - Drug Profile 223
LGX-818 - Drug Profile 225
HLA-A24 Restricted Epitope Peptide Cocktail Vaccine - Drug Profile 226
HMPL-013 - Drug Profile 227
ramucirumab - Drug Profile 228
cabozantinib (s)-malate - Drug Profile 232
irinotecan sucrosofate liposomal - Drug Profile 235
TF-2 - Drug Profile 238
dalotuzumab - Drug Profile 240
luminespib - Drug Profile 243
Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A + [bevacizumab] + [fluorouracil] + [irinotecan hydrochloride] + [leucovorin calcium] - Drug Profile 246
ziv-aflibercept - Drug Profile 247
PD-0325901 + PF-05212384 - Drug Profile 250
KPT-330 - Drug Profile 251
bevacizumab biosimilar - Drug Profile 253
cetuximab biosimilar - Drug Profile 254
bevacizumab biosimilar - Drug Profile 255
MLN-0264 - Drug Profile 256
bevacizumab biosmilar - Drug Profile 257
cetuximab biosimilar - Drug Profile 258
bevacizumab biosimilar - Drug Profile 259
cetuximab biosimilar - Drug Profile 260
bevacizumab biosimilar - Drug Profile 261
IBPM-002-BZ - Drug Profile 262
bevacizumab biosimilar - Drug Profile 263
bevacizumab biosimilar - Drug Profile 264
bevacizumab biosimilar - Drug Profile 265
cetuximab biosimilar - Drug Profile 266
Metastatic Colorectal Cancer - Recent Pipeline Updates 267
Metastatic Colorectal Cancer - Dormant Projects 369
Metastatic Colorectal Cancer - Discontinued Products 371
Metastatic Colorectal Cancer - Product Development Milestones 372
Featured News & Press Releases 372
Appendix 382
Methodology 382
Coverage 382
Secondary Research 382
Primary Research 382
Expert Panel Validation 382
Contact Us 383
Disclaimer 383 List of Tables
Number of Products under Development for Metastatic Colorectal Cancer, H1 2014 17
Number of Products under Development for Metastatic Colorectal Cancer - Comparative Analysis, H1 2014 18
Number of Products under Development by Companies, H1 2014 20
Number of Products under Development by Companies, H1 2014 (Contd..1) 21
Number of Products under Development by Companies, H1 2014 (Contd..2) 22
Number of Products under Development by Companies, H1 2014 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H1 2014 24
Comparative Analysis by Late Stage Development, H1 2014 25
Comparative Analysis by Clinical Stage Development, H1 2014 26
Comparative Analysis by Early Stage Development, H1 2014 27
Comparative Analysis by Unknown Stage Development, H1 2014 28
Products under Development by Companies, H1 2014 29
Products under Development by Companies, H1 2014 (Contd..1) 30
Products under Development by Companies, H1 2014 (Contd..2) 31
Products under Development by Companies, H1 2014 (Contd..3) 32
Products under Development by Companies, H1 2014 (Contd..4) 33
Products under Investigation by Universities/Institutes, H1 2014 34
Metastatic Colorectal Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2014 35
Metastatic Colorectal Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2014 36
Metastatic Colorectal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 37
Metastatic Colorectal Cancer - Pipeline by Amgen Inc., H1 2014 38
Metastatic Colorectal Cancer - Pipeline by AstraZeneca PLC, H1 2014 39
Metastatic Colorectal Cancer - Pipeline by Eli Lilly and Company, H1 2014 40
Metastatic Colorectal Cancer - Pipeline by Genentech, Inc., H1 2014 41
Metastatic Colorectal Cancer - Pipeline by Nektar Therapeutics, H1 2014 42
Metastatic Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H1 2014 43
Metastatic Colorectal Cancer - Pipeline by Merck & Co., Inc., H1 2014 44
Metastatic Colorectal Cancer - Pipeline by Light Sciences Oncology, Inc., H1 2014 45
Metastatic Colorectal Cancer - Pipeline by Celltrion, Inc., H1 2014 46
Metastatic Colorectal Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 47
Metastatic Colorectal Cancer - Pipeline by Novartis AG, H1 2014 48
Metastatic Colorectal Cancer - Pipeline by Biocon Limited, H1 2014 49
Metastatic Colorectal Cancer - Pipeline by Nippon Kayaku Co., Ltd., H1 2014 50
Metastatic Colorectal Cancer - Pipeline by Pfizer Inc., H1 2014 51
Metastatic Colorectal Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2014 52
Metastatic Colorectal Cancer - Pipeline by Exelixis, Inc., H1 2014 53
Metastatic Colorectal Cancer - Pipeline by Bayer AG, H1 2014 54
Metastatic Colorectal Cancer - Pipeline by Merck KGaA, H1 2014 55
Metastatic Colorectal Cancer - Pipeline by Alchemia Limited, H1 2014 56
Metastatic Colorectal Cancer - Pipeline by Immunomedics, Inc., H1 2014 57
Metastatic Colorectal Cancer - Pipeline by Oncolytics Biotech Inc., H1 2014 58
Metastatic Colorectal Cancer - Pipeline by Oncothyreon Inc., H1 2014 59
Metastatic Colorectal Cancer - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2014 60
Metastatic Colorectal Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2014 61
Metastatic Colorectal Cancer - Pipeline by Panacea Biotec Limited, H1 2014 62
Metastatic Colorectal Cancer - Pipeline by Morphotek, Inc., H1 2014 63
Metastatic Colorectal Cancer - Pipeline by Glycotope GmbH., H1 2014 64
Metastatic Colorectal Cancer - Pipeline by Hutchison MediPharma Limited, H1 2014 65
Metastatic Colorectal Cancer - Pipeline by TetraLogic Pharmaceuticals, H1 2014 66
Metastatic Colorectal Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2014 67
Metastatic Colorectal Cancer - Pipeline by Jennerex Biotherapeutics, Inc., H1 2014 68
Metastatic Colorectal Cancer - Pipeline by Syndax Pharmaceuticals, Inc., H1 2014 69
Metastatic Colorectal Cancer - Pipeline by Globeimmune, Inc., H1 2014 70
Metastatic Colorectal Cancer - Pipeline by AB Science, H1 2014 71
Metastatic Colorectal Cancer - Pipeline by CureTech Ltd., H1 2014 72
Metastatic Colorectal Cancer - Pipeline by Biothera, Inc., H1 2014 73
Metastatic Colorectal Cancer - Pipeline by Medical Enzymes AG, H1 2014 74
Metastatic Colorectal Cancer - Pipeline by Oncozyme Pharma Inc., H1 2014 75
Metastatic Colorectal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2014 76
Metastatic Colorectal Cancer - Pipeline by Immodulon Therapeutics Ltd., H1 2014 77
Metastatic Colorectal Cancer - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2014 78
Metastatic Colorectal Cancer - Pipeline by PsiOxus Therapeutics, Ltd., H1 2014 79
Metastatic Colorectal Cancer - Pipeline by AlphaMab Co., Ltd, H1 2014 80
Assessment by Monotherapy Products, H1 2014 81
Assessment by Combination Products, H1 2014 82
Number of Products by Stage and Target, H1 2014 85
Number of Products by Stage and Mechanism of Action, H1 2014 90
Number of Products by Stage and Route of Administration, H1 2014 95
Number of Products by Stage and Molecule Type, H1 2014 98
Metastatic Colorectal Cancer Therapeutics - Recent Pipeline Updates, H1 2014 273
Metastatic Colorectal Cancer - Dormant Projects, H1 2014 375
Metastatic Colorectal Cancer - Discontinued Products, H1 2014 377List of Figures
Number of Products under Development for Metastatic Colorectal Cancer, H1 2014 17
Number of Products under Development for Metastatic Colorectal Cancer - Comparative Analysis, H1 2014 18
Number of Products under Development by Companies, H1 2014 19
Number of Products under Investigation by Universities/Institutes, H1 2014 24
Comparative Analysis by Late Stage Development, H1 2014 25
Comparative Analysis by Clinical Stage Development, H1 2014 26
Comparative Analysis by Early Stage Products, H1 2014 27
Assessment by Monotherapy Products, H1 2014 81
Assessment by Combination Products, H1 2014 82
Number of Products by Top 10 Target, H1 2014 83
Number of Products by Stage and Top 10 Target, H1 2014 84
Number of Products by Top 10 Mechanism of Action, H1 2014 88
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 89
Number of Products by Top 10 Route of Administration, H1 2014 93
Number of Products by Stage and Top 10 Route of Administration, H1 2014 94
Number of Products by Top 10 Molecule Type, H1 2014 96
Number of Products by Stage and Top 10 Molecule Type, H1 2014 97